Substituted bicyclic compounds
US-9522888-B2 · Dec 20, 2016 · US
US10087199B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10087199-B2 |
| Application number | US-201514919216-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 21, 2015 |
| Priority date | Oct 22, 2014 |
| Publication date | Oct 2, 2018 |
| Grant date | Oct 2, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides compositions that may be used for imaging intracellular structures. The invention further provides methods of imaging intracellular structures. In certain embodiments, the compositions of the invention include trans-cyclooctene-containing ceramide lipids and tetrazine-containing rhodamine-related dyes.
Opening claim text (preview).
What is claimed: 1. A trans-cyclooctene-containing lipid, or a salt, solvate, stereoisomer, or any mixtures thereof, wherein the lipid comprises TCO-LINK-LIPID, wherein TCO is a trans-cyclooctene group, LINK is a bivalent linker, and wherein LIPID comprises at least one selected from the group consisting of a sphingolipid, phospholipid, sterol lipid and fatty acid wherein LINK comprises: —X(CR′R″) n C(═O)—, wherein X is covalently conjugated to TCO and is selected from the group consisting of a covalent bond, —C(═O)—, —C(═O)O— and —C(═O)NR′—; each occurrence of R′ and R″ is independently selected from the group consisting of H and optionally substituted C 1 -C 6 alkyl; and n is an integer ranging from 1 to 20. 2. The trans-cyclooctene-containing lipid of claim 1 , wherein TCO is selected from the group consisting of: wherein R′ is H or optionally substituted C 1 -C 6 alkyl, and wherein the heteroatom is not attached to the ring double bond. 3. The trans-cyclooctene-containing lipid of claim 2 , wherein TCO is selected from the group consisting of: wherein R′ is H or optionally substituted C 1 -C 6 alkyl. 4. The trans-cyclooctene-containing lipid of claim 1 , wherein LIPID comprises at least one selected from the group consisting of sphingosine, 1-phosphocholine-sphingosine, 1-phosphoethanolamine-sphingosine, and a 1-glycosyl-sphingosine. 5. The trans-cyclooctene-containing lipid of claim 4 , wherein LIPID comprises sphingosine. 6. The trans-cyclooctene-containing lipid of claim 5 , wherein LIPID comprises sphingosine and is covalently conjugated to LINK through the 2-amino group of sphingosine. 7. The trans-cyclooctene-containing lipid of claim 1 , wherein n is 5. 8. The trans-cyclooctene-containing lipid of claim 1 , which is Cer-TCO or a salt, solvate, stereoisomer, or any mixtures thereof:
said ring comprising Si as a ring atom · CPC title
with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms · CPC title
comprising Si as a ring atom · CPC title
with a ring being at least seven-membered · CPC title
with fluorescent label · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.